• A long-time Safety Standdown supporter, Boedigheimer has demonstrated exceptional safety leadership throughout his esteemed 30-plus year career
  • Influential award recognizes exceptional efforts to continue to enhance aviation safety throughout the industry
  • Bombardier’s Safety Standdown is celebrating 30 years of aviation safety stewardship and education providing life-long learning opportunities for aviation professionals around the world

Image (13)

MONTREAL, Nov. 12, 2026 (GLOBE NEWSWIRE) — Bombardier today announced that Dan Boedigheimer, Ph. D., is the winner of this year’s Bombardier Safety Standdown Award, handed out annually to a deserving aviation professional that has demonstrated an uncompromising commitment to enhancing safety throughout their career. Boedigheimer received the honour during a gala dinner on the final night of the three-day milestone event which brought together more than 400 aviation professionals to Wichita, Kansas.

With more than 30 years in aviation and aerospace, Boedigheimer is a talented Chief Safety Officer who has demonstrated a history of redefining safety in the aviation and aerospace industries. Throughout his career, he has consistently applied his strong training and business development acumen to develop and lead countless aviation professionals in their careers.

“On behalf of Bombardier, I wish to congratulate Dan for his outstanding career and unwavering commitment to Safety Standdown and to promoting aviation safety and professionalism at all levels of our industry for a quarter of a century,” said Chris Milligan, Vice President, Pre-owned Aircraft Services and Flight Operations, Bombardier. “Dan embodies precisely what the Safety Standdown Award stands for: celebrating aviation professionals who are role models in the field and have made a real difference with everything they do. He is a true ambassador for our Safety Standdown mission.”

“Bombardier Safety Standdown has had a profound impact on me, both professionally and personally, since I first attended in 2008. The knowledge I’ve gained, the relationships I’ve built, and the mentors who have challenged me to raise my own standards have shaped my career in ways I never could have imagined,” said Dan Boedigheimer, Ph. D. “I’ve always believed that advancing aviation safety requires us to go beyond simply meeting the minimums, and Safety Standdown brings together people who live that philosophy. I’m deeply honored to receive this award, particularly knowing how much more I’ve gained from this extraordinary community than I could ever give back.”

As a founding partner of Advanced Aircrew Academy, Boedigheimer holds the role of Chief Safety Officer, following a stint as CEO at the company for close to 18 years. Prior to that, he was the Lead Human Factors Instructor at Convergent Performance LLC, and the Manager of Aircraft Standards and Training at Flight Options.

The inspiration for Boedigheimer’s dissertation came from attending Safety Standdown in 2006 and hearing Tony Kern’s message on the Global War on Error. Four years later, his FAA-sponsored dissertation, Exploring Pilot Reliability Certification and Changing Attitudes on the Reduction of Errors, was published in the Transportation Research Record.

Boedigheimer recently completed his tenure as Chairman of the NBAA Safety Committee. He also currently serves on the IBAC IS-BAO Standards Board, reviews for the Embry-Riddle Journal of Aviation/Aerospace Education and Research, and serves on the board of the Colorado Aviation Network.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of more than 5,200 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service centres across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.     

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Matthew Nicholls
+1-514-243-8214
Matthew.Nicholls@aero.bombardier.com

Bombardier and Safety Standdown are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e0c07938-224c-43ec-841c-329a80411b3f

  • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from Eikon’s PARP1-selective inhibitor and Werner (WRN) helicase inhibitor programs and updated EIK1001 data from TeLuRide-005, a Phase 2 trial in non-small cell lung cancer (NSCLC)
  • Dosed first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab and chemotherapy in NSCLC
  • Submitted an Investigational New Drug (IND) application for EIK1006, a novel non-lutamide androgen receptor (AR) antagonist with broad activity against wild type and AR variants associated with treatment failure in patients with prostate cancer
  • Appointed Ching-Pin Chang, M.D., Ph.D., as Chief Scientific Officer
  • Ended third quarter 2026 with $461.7 million in cash, cash equivalents and marketable securities; updating runway guidance into the first quarter of 2028 based on continued fiscal discipline and operating leverage

MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported third quarter 2026 financial results and provided updates on its programs.

“The third quarter was marked by important progress across Eikon’s oncology programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “At the 2026 ESMO Congress, we presented updated results from TeLuRide-005, providing additional evidence of durable anti-tumor activity for EIK1001 in combination with standard-of-care therapy in squamous NSCLC, building on earlier data in non-squamous NSCLC that we shared at ASCO. We also presented encouraging activity and tolerability data across our selective PARP1 inhibitor programs, supporting their continued development, alongside initial findings from our WRN inhibitor program. Taken together, these findings demonstrate the breadth of our clinical portfolio and reflect our broader mission at Eikon to translate rigorous science into innovative medicines with the potential to address important unmet needs in cancer therapy.”

Clinical Development Highlights

EIK1001

EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to stimulate both innate and adaptive immune responses to malignancy. Intravenous administration of EIK1001 has been observed to be generally well-tolerated, shown a pharmacodynamic profile consistent with systemic immune responses, and can be combined with current standard-of-care.

  • On October 26, 2026, Eikon presented updated data at the 2026 ESMO Congress from TeLuRide-005 (NCT06246110), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with NSCLC. Among other results, the presentation showed:
    • Across the pooled efficacy-evaluable population (n=65), EIK1001 in combination with pembrolizumab and chemotherapy resulted in an objective response rate (ORR) of 63.1% and disease control rate (DCR) of 89.2% at a median follow-up of 17.2 months, with objective responses observed across all PD-L1 tumor proportion score (TPS) subgroups.
    • In the squamous cohort, ORR was 72.4% and DCR was 100%, with a median duration of response (DOR) of 12.9 months at a median follow-up of 12.7 months.
    • In the non-squamous cohort, ORR was 55.6% and DCR was 80.6%, with a median DOR of 11.2 months at a median follow-up of 17.9 months.
    • The combination was generally well-tolerated, with an adverse event profile similar to standard-of-care alone and a tolerability profile supportive of systemic administration of EIK1001 in an outpatient setting.
  • On July 27, 2026, Eikon announced dosing of the first patient in TeLuRide-008 (NCT07365319), a Phase 2/3 registrational trial evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 NSCLC. The trial is actively enrolling, with a prespecified interim analysis for dose selection anticipated in the second half of 2027.

EIK1003 & EIK1004

EIK1003 and EIK1004 are highly selective PARP1 inhibitors designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1004 was specifically engineered to penetrate the central nervous system (CNS), potentially expanding the utility of selective PARP1 inhibition to tumors involving the brain. The selectivity of EIK1003 and EIK1004 may enable the development of near full-dose combination regimens with chemotherapy, antibody-drug conjugates, or radionuclides, in earlier lines of therapy than currently possible with non-selective PARP inhibitors, and potentially allow for more sustained therapeutic dosing during maintenance treatment.

  • On October 23, 2026, Eikon presented updated and initial clinical data at the 2026 ESMO Congress from its ongoing Phase 1/2 trial evaluating EIK1003 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid tumors (NCT06253130). Among other results, the presentations showed:
    • In Cohort 1A, evaluating EIK1003 monotherapy, EIK1003 was generally well-tolerated across multiple dose levels. Among 49 efficacy-evaluable participants, the ORR was 14.3% overall and 31.3% among PARP inhibitor-naïve participants.
    • In Cohort 1B, evaluating EIK1003 in combination with abiraterone in patients with metastatic prostate cancer, the combination demonstrated a favorable tolerability profile and preliminary anti-tumor activity, including an ORR of 20.8% among 24 RECIST-evaluable participants and a prostate-specific antigen (PSA) response (greater than or equal to 50% from baseline) in 30.8% of PSA-evaluable participants.
    • In Cohort 1C, evaluating EIK1003 in combination with weekly paclitaxel in patients with ovarian or breast cancer that had failed appropriate therapy, signals of anti-tumor activity were observed, with an ORR of 26.4% among 53 efficacy-evaluable participants, including one confirmed complete response and 13 partial responses, and with 86% of responders having had prior taxane exposure.
  • On October 23, 2026, Eikon also presented initial clinical data at the 2026 ESMO Congress from its ongoing Phase 1/2 trial evaluating EIK1004 (NCT06907043). EIK1004 was generally well-tolerated, with minimal hematologic toxicity, across multiple dose levels. Among 58 efficacy-evaluable participants, ORR was 12.1% and DCR was 62.1%, with responses observed in breast, ovarian and prostate cancers.

EIK1005

EIK1005 is a novel molecular entity, designed to inhibit the Werner (WRN) helicase, that emerged from original research conducted in Eikon’s laboratories. EIK1005 has the potential to be an effective anti-tumor agent for microsatellite instability-high (MSI-high) tumors by producing synthetic lethality in MSI-high cells that depend upon the WRN helicase salvage pathway to maintain genome integrity.

  • On October 23, 2026, Eikon presented preliminary clinical data at the 2026 ESMO Congress from EIK1005-002, an ongoing Phase 1/2 trial evaluating EIK1005 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors (NCT07262619). Among other results, the presentation showed:
    • EIK1005 was generally well tolerated and demonstrated a pharmacokinetic profile supporting once-weekly administration.
    • 6 of 8 efficacy-evaluable participants in the monotherapy dose-escalation portion achieved stable disease (SD), all of whom had confirmed DNA mismatch repair deficiency (dMMR) or MSI-high tumors.
    • The first participant enrolled in the combination dose-escalation portion with pembrolizumab achieved a partial response at the first post-baseline scan.

EIK1006

EIK1006 is an internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (AR) antagonist with activity against wild type and multiple clinically important genetic variants of AR that emerge during treatment with conventional AR antagonists. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.

  • On October 14, 2026, Eikon submitted an IND application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.

Key Upcoming Milestones

  • EIK1001: Prespecified interim analysis for advancement to Phase 3 for TeLuRide-006, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab in advanced melanoma, is anticipated in the first half of 2027, and prespecified interim analysis for dose selection in the ongoing TeLuRide-008 Phase 2/3 trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line treatment for patients with stage 4 NSCLC is anticipated in the second half of 2027.
  • EIK1003: Eikon expects initial results from Cohort 1D of the ongoing Phase 1/2 study evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy in the second half of 2027, and expects to complete the ongoing Phase 2 dose-optimization portion of the EIK1003 trial in the second half of 2027.
  • EIK1004: Eikon plans to initiate a combination arm in the Phase 1/2 study to evaluate EIK1004 with docetaxel in patients with castrate-resistant prostate cancer and expects to report initial results from that combination arm in the second half of 2027.
  • EIK1005: Eikon expects additional results from the Phase 1/2 study evaluating EIK1005 in combination with pembrolizumab in the first half of 2027 and complete results from the EIK1005 monotherapy portion of the trial in the second half of 2027.
  • EIK1006: Subject to FDA clearance, Eikon plans to initiate a Phase 1/2 study in metastatic prostate cancer and anticipates preliminary safety and efficacy data to be available in the second half of 2027.

Third Quarter 2026 Corporate Highlights

Appointment of Ching-Pin (CP) Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

On September 3, 2026, Eikon appointed Ching-Pin “CP” Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist with more than two decades of experience spanning academic medicine, fundamental research and drug discovery. He joined Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology. Previously, he served in research leadership roles at Gilead Sciences, at MyoKardia and held academic positions at Stanford University and at the Indiana University School of Medicine.

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $461.7 million. Net cash used in operating activities was $224.0 million for the nine months ended September 30, 2026. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.

Research and Development (R&D) Expenses: R&D expenses were $71.8 million for the three months ended September 30, 2026 compared to $59.3 million for the three months ended September 30, 2025, an increase of $12.5 million, or 21%. Direct research and development expenses increased $9.2 million as we advanced our clinical trial activity, and compensation costs increased $3.0 million.

General and Administrative (G&A) Expenses: G&A expenses were $18.7 million for the three months ended September 30, 2026, compared to $15.4 million for the three months ended September 30, 2025, an increase of $3.3 million, or 21%. This increase was primarily due to $1.5 million higher professional fees from consulting and legal expenses and $1.1 million higher other operating expenses, primarily IT expenses.

Net Loss: Net loss attributable to common stockholders was $86.1 million for the third quarter of 2026, as compared to $71.1 million for the prior-year period.

“We ended the third quarter with $461.7 million in cash and are updating our runway guidance into the first quarter of 2028, through the key clinical milestones anticipated in 2027,” said Freddie Bowie, Ph.D., Chief Financial Officer. “We have remained focused on disciplined capital allocation. Operating expenses for the nine months ended September 30, 2026 increased 6% year over year, with G&A down 24% and R&D representing 80% of the total. We are concentrating investment behind our most advanced programs and tying incremental spending to clinical milestones, with the goal of creating long-term shareholder value.”

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including the anticipated cash runway into the first quarter of 2028; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: Eikon’s limited operating history; its significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; its need for substantial additional funding; the early stage of development of many of its product candidates and the possibility that its product candidates may fail in development; its dependence on the success of its current product candidates; its ability to leverage its technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) on November 12, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

Eikon Therapeutics, Inc.
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)

  (in thousands, except share and per share amounts)
   
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Operating expenses:              
Research and development $ 71,826     $ 59,313     $ 217,333     $ 185,089  
General and administrative   18,726       15,438       53,950       70,688  
Total operating expenses   90,552       74,751       271,283       255,777  
Loss from operations   (90,552 )     (74,751 )     (271,283 )     (255,777 )
Interest income (expense), net   4,486       3,613       13,903       11,207  
Other income (expense), net   (46 )     (1 )     (99 )     (23 )
Net loss and comprehensive loss   (86,112 )     (71,139 )     (257,479 )     (244,593 )
Impact of preferred stock
extinguishments and modifications
  —       —       —       (9,396 )
Net loss attributable to common stockholders $ (86,112 )   $ (71,139 )   $ (257,479 )   $ (253,989 )
Net loss per share attributable to
common stockholders, basic and
diluted
$ (1.59 )   $ (24.24 )   $ (5.43 )   $ (89.06 )
Weighted-average shares of common
stock outstanding used in
computing net loss per share
attributable to common
stockholders, basic and diluted
  54,168,268       2,934,921       47,412,330       2,851,910  

Eikon Therapeutics, Inc.
Condensed Balance Sheet Data
(in thousands)
(Unaudited)

  (in thousands)
  September 30,
2026
  December 31,
2025
Cash, cash equivalents and marketable
securities
$ 461,717   $ 335,975  
Total assets   706,201     594,734  
Total liabilities   321,908     312,298  
Total stockholders’ equity (deficit)   384,293     (879,034 )

  • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from Eikon’s PARP1-selective inhibitor and Werner (WRN) helicase inhibitor programs and updated EIK1001 data from TeLuRide-005, a Phase 2 trial in non-small cell lung cancer (NSCLC)
  • Dosed first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab and chemotherapy in NSCLC
  • Submitted an Investigational New Drug (IND) application for EIK1006, a novel non-lutamide androgen receptor (AR) antagonist with broad activity against wild type and AR variants associated with treatment failure in patients with prostate cancer
  • Appointed Ching-Pin Chang, M.D., Ph.D., as Chief Scientific Officer
  • Ended third quarter 2026 with $461.7 million in cash, cash equivalents and marketable securities; updating runway guidance into the first quarter of 2028 based on continued fiscal discipline and operating leverage

MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported third quarter 2026 financial results and provided updates on its programs.

“The third quarter was marked by important progress across Eikon’s oncology programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “At the 2026 ESMO Congress, we presented updated results from TeLuRide-005, providing additional evidence of durable anti-tumor activity for EIK1001 in combination with standard-of-care therapy in squamous NSCLC, building on earlier data in non-squamous NSCLC that we shared at ASCO. We also presented encouraging activity and tolerability data across our selective PARP1 inhibitor programs, supporting their continued development, alongside initial findings from our WRN inhibitor program. Taken together, these findings demonstrate the breadth of our clinical portfolio and reflect our broader mission at Eikon to translate rigorous science into innovative medicines with the potential to address important unmet needs in cancer therapy.”

Clinical Development Highlights

EIK1001

EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to stimulate both innate and adaptive immune responses to malignancy. Intravenous administration of EIK1001 has been observed to be generally well-tolerated, shown a pharmacodynamic profile consistent with systemic immune responses, and can be combined with current standard-of-care.

  • On October 26, 2026, Eikon presented updated data at the 2026 ESMO Congress from TeLuRide-005 (NCT06246110), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with NSCLC. Among other results, the presentation showed:
    • Across the pooled efficacy-evaluable population (n=65), EIK1001 in combination with pembrolizumab and chemotherapy resulted in an objective response rate (ORR) of 63.1% and disease control rate (DCR) of 89.2% at a median follow-up of 17.2 months, with objective responses observed across all PD-L1 tumor proportion score (TPS) subgroups.
    • In the squamous cohort, ORR was 72.4% and DCR was 100%, with a median duration of response (DOR) of 12.9 months at a median follow-up of 12.7 months.
    • In the non-squamous cohort, ORR was 55.6% and DCR was 80.6%, with a median DOR of 11.2 months at a median follow-up of 17.9 months.
    • The combination was generally well-tolerated, with an adverse event profile similar to standard-of-care alone and a tolerability profile supportive of systemic administration of EIK1001 in an outpatient setting.
  • On July 27, 2026, Eikon announced dosing of the first patient in TeLuRide-008 (NCT07365319), a Phase 2/3 registrational trial evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 NSCLC. The trial is actively enrolling, with a prespecified interim analysis for dose selection anticipated in the second half of 2027.

EIK1003 & EIK1004

EIK1003 and EIK1004 are highly selective PARP1 inhibitors designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1004 was specifically engineered to penetrate the central nervous system (CNS), potentially expanding the utility of selective PARP1 inhibition to tumors involving the brain. The selectivity of EIK1003 and EIK1004 may enable the development of near full-dose combination regimens with chemotherapy, antibody-drug conjugates, or radionuclides, in earlier lines of therapy than currently possible with non-selective PARP inhibitors, and potentially allow for more sustained therapeutic dosing during maintenance treatment.

  • On October 23, 2026, Eikon presented updated and initial clinical data at the 2026 ESMO Congress from its ongoing Phase 1/2 trial evaluating EIK1003 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid tumors (NCT06253130). Among other results, the presentations showed:
    • In Cohort 1A, evaluating EIK1003 monotherapy, EIK1003 was generally well-tolerated across multiple dose levels. Among 49 efficacy-evaluable participants, the ORR was 14.3% overall and 31.3% among PARP inhibitor-naïve participants.
    • In Cohort 1B, evaluating EIK1003 in combination with abiraterone in patients with metastatic prostate cancer, the combination demonstrated a favorable tolerability profile and preliminary anti-tumor activity, including an ORR of 20.8% among 24 RECIST-evaluable participants and a prostate-specific antigen (PSA) response (greater than or equal to 50% from baseline) in 30.8% of PSA-evaluable participants.
    • In Cohort 1C, evaluating EIK1003 in combination with weekly paclitaxel in patients with ovarian or breast cancer that had failed appropriate therapy, signals of anti-tumor activity were observed, with an ORR of 26.4% among 53 efficacy-evaluable participants, including one confirmed complete response and 13 partial responses, and with 86% of responders having had prior taxane exposure.
  • On October 23, 2026, Eikon also presented initial clinical data at the 2026 ESMO Congress from its ongoing Phase 1/2 trial evaluating EIK1004 (NCT06907043). EIK1004 was generally well-tolerated, with minimal hematologic toxicity, across multiple dose levels. Among 58 efficacy-evaluable participants, ORR was 12.1% and DCR was 62.1%, with responses observed in breast, ovarian and prostate cancers.

EIK1005

EIK1005 is a novel molecular entity, designed to inhibit the Werner (WRN) helicase, that emerged from original research conducted in Eikon’s laboratories. EIK1005 has the potential to be an effective anti-tumor agent for microsatellite instability-high (MSI-high) tumors by producing synthetic lethality in MSI-high cells that depend upon the WRN helicase salvage pathway to maintain genome integrity.

  • On October 23, 2026, Eikon presented preliminary clinical data at the 2026 ESMO Congress from EIK1005-002, an ongoing Phase 1/2 trial evaluating EIK1005 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors (NCT07262619). Among other results, the presentation showed:
    • EIK1005 was generally well tolerated and demonstrated a pharmacokinetic profile supporting once-weekly administration.
    • 6 of 8 efficacy-evaluable participants in the monotherapy dose-escalation portion achieved stable disease (SD), all of whom had confirmed DNA mismatch repair deficiency (dMMR) or MSI-high tumors.
    • The first participant enrolled in the combination dose-escalation portion with pembrolizumab achieved a partial response at the first post-baseline scan.

EIK1006

EIK1006 is an internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (AR) antagonist with activity against wild type and multiple clinically important genetic variants of AR that emerge during treatment with conventional AR antagonists. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.

  • On October 14, 2026, Eikon submitted an IND application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.

Key Upcoming Milestones

  • EIK1001: Prespecified interim analysis for advancement to Phase 3 for TeLuRide-006, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab in advanced melanoma, is anticipated in the first half of 2027, and prespecified interim analysis for dose selection in the ongoing TeLuRide-008 Phase 2/3 trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line treatment for patients with stage 4 NSCLC is anticipated in the second half of 2027.
  • EIK1003: Eikon expects initial results from Cohort 1D of the ongoing Phase 1/2 study evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy in the second half of 2027, and expects to complete the ongoing Phase 2 dose-optimization portion of the EIK1003 trial in the second half of 2027.
  • EIK1004: Eikon plans to initiate a combination arm in the Phase 1/2 study to evaluate EIK1004 with docetaxel in patients with castrate-resistant prostate cancer and expects to report initial results from that combination arm in the second half of 2027.
  • EIK1005: Eikon expects additional results from the Phase 1/2 study evaluating EIK1005 in combination with pembrolizumab in the first half of 2027 and complete results from the EIK1005 monotherapy portion of the trial in the second half of 2027.
  • EIK1006: Subject to FDA clearance, Eikon plans to initiate a Phase 1/2 study in metastatic prostate cancer and anticipates preliminary safety and efficacy data to be available in the second half of 2027.

Third Quarter 2026 Corporate Highlights

Appointment of Ching-Pin (CP) Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

On September 3, 2026, Eikon appointed Ching-Pin “CP” Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist with more than two decades of experience spanning academic medicine, fundamental research and drug discovery. He joined Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology. Previously, he served in research leadership roles at Gilead Sciences, at MyoKardia and held academic positions at Stanford University and at the Indiana University School of Medicine.

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $461.7 million. Net cash used in operating activities was $224.0 million for the nine months ended September 30, 2026. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.

Research and Development (R&D) Expenses: R&D expenses were $71.8 million for the three months ended September 30, 2026 compared to $59.3 million for the three months ended September 30, 2025, an increase of $12.5 million, or 21%. Direct research and development expenses increased $9.2 million as we advanced our clinical trial activity, and compensation costs increased $3.0 million.

General and Administrative (G&A) Expenses: G&A expenses were $18.7 million for the three months ended September 30, 2026, compared to $15.4 million for the three months ended September 30, 2025, an increase of $3.3 million, or 21%. This increase was primarily due to $1.5 million higher professional fees from consulting and legal expenses and $1.1 million higher other operating expenses, primarily IT expenses.

Net Loss: Net loss attributable to common stockholders was $86.1 million for the third quarter of 2026, as compared to $71.1 million for the prior-year period.

“We ended the third quarter with $461.7 million in cash and are updating our runway guidance into the first quarter of 2028, through the key clinical milestones anticipated in 2027,” said Freddie Bowie, Ph.D., Chief Financial Officer. “We have remained focused on disciplined capital allocation. Operating expenses for the nine months ended September 30, 2026 increased 6% year over year, with G&A down 24% and R&D representing 80% of the total. We are concentrating investment behind our most advanced programs and tying incremental spending to clinical milestones, with the goal of creating long-term shareholder value.”

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including the anticipated cash runway into the first quarter of 2028; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: Eikon’s limited operating history; its significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; its need for substantial additional funding; the early stage of development of many of its product candidates and the possibility that its product candidates may fail in development; its dependence on the success of its current product candidates; its ability to leverage its technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) on November 12, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

Eikon Therapeutics, Inc.
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)

  (in thousands, except share and per share amounts)
   
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Operating expenses:              
Research and development $ 71,826     $ 59,313     $ 217,333     $ 185,089  
General and administrative   18,726       15,438       53,950       70,688  
Total operating expenses   90,552       74,751       271,283       255,777  
Loss from operations   (90,552 )     (74,751 )     (271,283 )     (255,777 )
Interest income (expense), net   4,486       3,613       13,903       11,207  
Other income (expense), net   (46 )     (1 )     (99 )     (23 )
Net loss and comprehensive loss   (86,112 )     (71,139 )     (257,479 )     (244,593 )
Impact of preferred stock
extinguishments and modifications
  —       —       —       (9,396 )
Net loss attributable to common stockholders $ (86,112 )   $ (71,139 )   $ (257,479 )   $ (253,989 )
Net loss per share attributable to
common stockholders, basic and
diluted
$ (1.59 )   $ (24.24 )   $ (5.43 )   $ (89.06 )
Weighted-average shares of common
stock outstanding used in
computing net loss per share
attributable to common
stockholders, basic and diluted
  54,168,268       2,934,921       47,412,330       2,851,910  

Eikon Therapeutics, Inc.
Condensed Balance Sheet Data
(in thousands)
(Unaudited)

  (in thousands)
  September 30,
2026
  December 31,
2025
Cash, cash equivalents and marketable
securities
$ 461,717   $ 335,975  
Total assets   706,201     594,734  
Total liabilities   321,908     312,298  
Total stockholders’ equity (deficit)   384,293     (879,034 )

Up to 207 MW of firm, contracted power for TCDC Phase 1, with availability expected in Q3 2027

In advanced negotiations on the Phase 1 lease documentation under a non-binding LOI covering TCDC Phases 1 and 2

MIDLAND, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer of next-generation digital infrastructure and integrated power assets, today provided a business update for the quarter ended September 30, 2026.

“Since our last quarterly update, we have contracted up to 207 MW of TCDC Phase 1 power, posted the required cash collateral and strengthened our balance sheet. With power availability expected in the third quarter of 2027, our focus is on our advanced negotiations for the Phase 1 lease and putting the financing and delivery arrangements in place,” said Charlie Nelson, Chairman and Chief Executive Officer of New Era.

“Responsible development has guided our approach from day one. That means designing power arrangements to avoid additional transmission costs for ratepayers, using water responsibly and giving local communities a voice. We want Texans to have a seat at the table and local residents and businesses to share in the opportunities TCDC creates.”

Recent Highlights

Texas Critical Data Centers LLC (“TCDC”) Leasing and Delivery

  • Executed a 20-year power purchase agreement (“PPA”) with Luminant, ET Services Company, LLC, an affiliate of Vistra Corp, for a minimum of 200 MW and up to 207 MW of firm power. Power availability is expected in the third quarter of 2027, with initial ready-for-service targeted for the fourth quarter of 2027
  • In advanced negotiations on the Phase 1 lease documentation under a non-binding LOI covering Phases 1 and 2 with the same prospective tenant
  • Site preparation is underway and an additional 99 acres are under contract, alongside the existing 493 acres owned

Responsible Development in Texas

  • Power and ratepayers: Phase 1 uses an existing registered, behind-the-meter private use network outside the Electric Reliability Council of Texas’ Batch Zero process. Phase 2 plans add new on-site generation to serve the additional demand directly. These arrangements are designed to avoid passing additional transmission costs on to other Texas ratepayers
  • Water stewardship: TCDC’s design prioritizes closed-loop cooling to limit water consumption. The Company is evaluating reuse of water produced by Permian Basin oil and gas operations for cooling, with the potential to reduce freshwater demand and volumes sent to disposal wells
  • Texans a seat at the table: Continuing direct engagement with local officials, businesses and community organizations in Odessa and Ector County, alongside efforts to support local employment and work with local suppliers and contractors

Financial Position

  • Completed a $64 million PIPE to repay Macquarie borrowings used to fund a portion of the Phase 1 PPA cash collateral, and support TCDC leasing and development
  • At October 31, 2026, total cash was $187 million, comprising $49 million of unrestricted cash and $138 million of restricted cash, including collateral supporting the PPA letter of credit
  • Outstanding debt at October 31, 2026 was $20 million and was cash collateralized
  • Retained the option for up to $200 million of post-lease financing under the Macquarie facility, subject to applicable financing conditions

TCDC Phases 2 and 3

  • Phase 2 plans include approximately 550 MW of new behind-the-meter generation with Thunderhead Energy Solutions, with the air permit application filed
  • Phase 3 remains in design

Business Update Call Details
Time and Date: 8:00 a.m. Eastern Time, Thursday, November 12, 2026

Access Option Registration Link
Live Webcast Use this link
Phone Dial-In with Live Q&A Use this link

A replay will be accessible shortly after the event on the Company’s investor relations website.

About New Era Energy & Digital, Inc.

New Era Energy & Digital is developing large-scale data centers across energy-rich U.S. markets to support AI training and inference workloads. New Era’s flagship project, Texas Critical Data Centers, is a 493-acre site located in the Permian Basin, with anticipated capacity scaling to over 1GW over time. New Era’s strategy is to combine large-acreage sites with flexible power solutions, including behind-the-meter power. New Era’s approach is a modular, phased data center deployment model, utilizing best-in-class water efficiency and self-generated power to minimize community impact and accelerate time-to-power for hyperscale, enterprise and edge operators.

For more information, visit: www.newerainfra.ai and follow New Era Energy & Digital on LinkedIn and X.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: our ability to construct, develop, lease and maintain our flagship project; our ability to realize the anticipated benefits of the power purchase agreement; our ability to access adequate project financing, commercial borrowings and debt and equity capital markets to fund our significant anticipated capital expenditures; the ability to obtain and maintain credit support to secure contractual obligations on commercially reasonable terms or at all; the impact of supply chain disruptions, labor availability, raw materials and input commodity costs and availability, and manufacturing and transportation; general business and economic conditions; environmental history, remediation, and associated risks; our ability to obtain and renew leases with our tenants on terms favorable to us, and manage our growth, business, financial results and results of operations; our ability to respond to price fluctuations and rapidly changing technology; the impact of tariffs and global trade disruptions on us and our tenants; changes in political conditions, geopolitical turmoil, political instability, civil disturbances, and restrictive governmental actions; the degree and nature of our competition; our failure to generate sufficient cash flows to service indebtedness; our expectations regarding the anticipated timeline of our cash, cash equivalents and short-term investments, future financial performance and our ability to continue as a going concern; material negative changes in the creditworthiness and the ability of our tenants to meet their contractual obligations; increases and volatility in interest rates; increased power, labor, equipment procurement, shipping, refurbishment or construction costs; a failure of our information technology systems, systems conversions and integrations, cybersecurity attacks or a breach of our information security systems, networks or processes; our inability to obtain and/or maintain necessary government or other required consents or permits; changes in, or the failure or inability to comply with, local, state, federal and applicable international laws and regulations, including related to taxation, real estate and zoning laws, and increases in real property tax rates; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect us; our ability to maintain an effective system of disclosure controls and procedures and internal control over financial reporting and operations; and other factors (including the risks contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our Form 10-Q for the quarterly period ended September 30, 2026). Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

For investor inquiries, please contact:

OG Advisory Group
Lincoln Tan
nuai@orangegroupadvisors.com

Up to 207 MW of firm, contracted power for TCDC Phase 1, with availability expected in Q3 2027

In advanced negotiations on the Phase 1 lease documentation under a non-binding LOI covering TCDC Phases 1 and 2

MIDLAND, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer of next-generation digital infrastructure and integrated power assets, today provided a business update for the quarter ended September 30, 2026.

“Since our last quarterly update, we have contracted up to 207 MW of TCDC Phase 1 power, posted the required cash collateral and strengthened our balance sheet. With power availability expected in the third quarter of 2027, our focus is on our advanced negotiations for the Phase 1 lease and putting the financing and delivery arrangements in place,” said Charlie Nelson, Chairman and Chief Executive Officer of New Era.

“Responsible development has guided our approach from day one. That means designing power arrangements to avoid additional transmission costs for ratepayers, using water responsibly and giving local communities a voice. We want Texans to have a seat at the table and local residents and businesses to share in the opportunities TCDC creates.”

Recent Highlights

Texas Critical Data Centers LLC (“TCDC”) Leasing and Delivery

  • Executed a 20-year power purchase agreement (“PPA”) with Luminant, ET Services Company, LLC, an affiliate of Vistra Corp, for a minimum of 200 MW and up to 207 MW of firm power. Power availability is expected in the third quarter of 2027, with initial ready-for-service targeted for the fourth quarter of 2027
  • In advanced negotiations on the Phase 1 lease documentation under a non-binding LOI covering Phases 1 and 2 with the same prospective tenant
  • Site preparation is underway and an additional 99 acres are under contract, alongside the existing 493 acres owned

Responsible Development in Texas

  • Power and ratepayers: Phase 1 uses an existing registered, behind-the-meter private use network outside the Electric Reliability Council of Texas’ Batch Zero process. Phase 2 plans add new on-site generation to serve the additional demand directly. These arrangements are designed to avoid passing additional transmission costs on to other Texas ratepayers
  • Water stewardship: TCDC’s design prioritizes closed-loop cooling to limit water consumption. The Company is evaluating reuse of water produced by Permian Basin oil and gas operations for cooling, with the potential to reduce freshwater demand and volumes sent to disposal wells
  • Texans a seat at the table: Continuing direct engagement with local officials, businesses and community organizations in Odessa and Ector County, alongside efforts to support local employment and work with local suppliers and contractors

Financial Position

  • Completed a $64 million PIPE to repay Macquarie borrowings used to fund a portion of the Phase 1 PPA cash collateral, and support TCDC leasing and development
  • At October 31, 2026, total cash was $187 million, comprising $49 million of unrestricted cash and $138 million of restricted cash, including collateral supporting the PPA letter of credit
  • Outstanding debt at October 31, 2026 was $20 million and was cash collateralized
  • Retained the option for up to $200 million of post-lease financing under the Macquarie facility, subject to applicable financing conditions

TCDC Phases 2 and 3

  • Phase 2 plans include approximately 550 MW of new behind-the-meter generation with Thunderhead Energy Solutions, with the air permit application filed
  • Phase 3 remains in design

Business Update Call Details
Time and Date: 8:00 a.m. Eastern Time, Thursday, November 12, 2026

Access Option Registration Link
Live Webcast Use this link
Phone Dial-In with Live Q&A Use this link

A replay will be accessible shortly after the event on the Company’s investor relations website.

About New Era Energy & Digital, Inc.

New Era Energy & Digital is developing large-scale data centers across energy-rich U.S. markets to support AI training and inference workloads. New Era’s flagship project, Texas Critical Data Centers, is a 493-acre site located in the Permian Basin, with anticipated capacity scaling to over 1GW over time. New Era’s strategy is to combine large-acreage sites with flexible power solutions, including behind-the-meter power. New Era’s approach is a modular, phased data center deployment model, utilizing best-in-class water efficiency and self-generated power to minimize community impact and accelerate time-to-power for hyperscale, enterprise and edge operators.

For more information, visit: www.newerainfra.ai and follow New Era Energy & Digital on LinkedIn and X.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: our ability to construct, develop, lease and maintain our flagship project; our ability to realize the anticipated benefits of the power purchase agreement; our ability to access adequate project financing, commercial borrowings and debt and equity capital markets to fund our significant anticipated capital expenditures; the ability to obtain and maintain credit support to secure contractual obligations on commercially reasonable terms or at all; the impact of supply chain disruptions, labor availability, raw materials and input commodity costs and availability, and manufacturing and transportation; general business and economic conditions; environmental history, remediation, and associated risks; our ability to obtain and renew leases with our tenants on terms favorable to us, and manage our growth, business, financial results and results of operations; our ability to respond to price fluctuations and rapidly changing technology; the impact of tariffs and global trade disruptions on us and our tenants; changes in political conditions, geopolitical turmoil, political instability, civil disturbances, and restrictive governmental actions; the degree and nature of our competition; our failure to generate sufficient cash flows to service indebtedness; our expectations regarding the anticipated timeline of our cash, cash equivalents and short-term investments, future financial performance and our ability to continue as a going concern; material negative changes in the creditworthiness and the ability of our tenants to meet their contractual obligations; increases and volatility in interest rates; increased power, labor, equipment procurement, shipping, refurbishment or construction costs; a failure of our information technology systems, systems conversions and integrations, cybersecurity attacks or a breach of our information security systems, networks or processes; our inability to obtain and/or maintain necessary government or other required consents or permits; changes in, or the failure or inability to comply with, local, state, federal and applicable international laws and regulations, including related to taxation, real estate and zoning laws, and increases in real property tax rates; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect us; our ability to maintain an effective system of disclosure controls and procedures and internal control over financial reporting and operations; and other factors (including the risks contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our Form 10-Q for the quarterly period ended September 30, 2026). Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

For investor inquiries, please contact:

OG Advisory Group
Lincoln Tan
nuai@orangegroupadvisors.com

Delivered same-store inside merchandise sales growth in 19 of the past 20 quarters and positive same-store fuel gallons growth for the fifth consecutive quarter

Opened two new stores in the third quarter, including first Arizona location

Reaffirmed full year 2026 outlook, reflecting continued momentum across the business

FORT WORTH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Yesway, Inc. (“Yesway” or the “Company”) (Nasdaq: YSWY), one of the fastest-growing convenience store operators in the United States, today announced financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights

  • Net income increased to $24.8 million from $15.9 million in the prior-year period, and Adjusted EBITDA increased 8.6% year-over-year to $59.6 million.
  • Same-store inside merchandise sales increased 1.9% year-over-year. Total inside merchandise sales increased 4.0% year-over-year, with a total inside merchandise margin of 35.1%.
  • Same-store fuel gallons sold increased 1.1% year-over-year. Total fuel gallons sold increased 4.8% year-over-year, with a total fuel margin of 46.1 cents per gallon.
  • Income from operations increased to $38.8 million from $35.4 million in the prior-year period, and Store Contribution increased 9.2% year-over-year to $77.0 million.

“We delivered another exceptional quarter, building on our strong performance in the first half of 2026,” said Thomas N. Trkla, Chairman, President and Chief Executive Officer of Yesway. “We continued to grow inside merchandise sales and fuel gallons, expand our market share, and deliver strong profitability against a challenging consumer environment. This continued momentum reflects our differentiated market positioning, deliberate geographic focus, significant diesel exposure, and destination foodservice platform.”

Mr. Trkla continued, “We are proud of what our team has accomplished and excited for what is ahead for Yesway as we continue to advance our three growth priorities – new store development, initiatives that strengthen our existing operations, and selective acquisitions – and drive long-term value for all our stakeholders.”

Third Quarter Results

Same-Store Comparison

Total fuel and inside merchandise gross profit increased 7.9% year-over-year on a same-store basis, reflecting growth in both fuel and inside merchandise categories.

Fuel gallons sold increased 1.1% year-over-year on a same-store basis, and same-store fuel gross profit increased 16.4% year-over-year.

Inside merchandise sales increased 1.9% year-over-year on a same-store basis, and same-store inside merchandise gross profit increased 1.4% year-over-year.

    Three months
ended September 30,
  Nine months
ended September 30,
Same-Store Year-Over-Year Comparison by Category (1)   2026 2025   2026 2025
Fuel Gallons   1.1 % 2.7 %   0.9 % 0.1 %
Fuel Gross Profit (2)   16.4 % 3.5 %   26.6 % 1.2 %
Inside Merchandise Sales   1.9 % 1.6 %   2.4 % 1.3 %
Inside Merchandise Gross Profit (3)   1.4 % 6.3 %   4.3 % 6.1 %
Total Fuel and Inside Merchandise Gross Profit   7.9 % 5.1 %   13.8 % 4.0 %
                     
  1. Same-store calculations for the current quarter and year-to-date periods ended September 30, 2026, exclude Iowa and Kansas locations that ceased operations prior to the end of the third quarter.
  2. Defined as fuel sales less cost of goods sold (exclusive of depreciation and amortization).
  3. Defined as inside merchandise sales less cost of goods sold (exclusive of depreciation and amortization).

Fuel

Fuel sales increased 51.6% year-over-year to $713.5 million, and fuel gross profit increased 19.8% year-over-year to $76.0 million, primarily driven by an increase in fuel margin cents per gallon, which increased 14.4% year-over-year to 46.1 cents per gallon, as well as increased fuel volumes.

 

  Three months
ended September 30,
  Nine months
ended September 30,
Fuel ($ in thousands)     2026     2025       2026     2025  
Fuel gallons sold (in thousands)     164,713     157,101       469,334     440,712  
Same-store gallons sold     1.1 %   2.7 %     0.9 %   0.1 %
Fuel Gross Profit   $ 75,972   $ 63,389     $ 231,565   $ 173,261  
Fuel Margin (cents per gallon)     46.1     40.3       49.3     39.3  
                             

Inside Merchandise

Inside merchandise sales increased 4.0% year-over-year to $246.4 million, and inside merchandise gross profit increased 3.8% year-over-year to $86.6 million, primarily driven by incremental sales resulting from a higher concentration of new stores, as well as pricing actions taken during 2026 and late 2025.

    Three months
ended September 30,
  Nine months
ended September 30,
Inside Merchandise ($ in thousands)     2026     2025       2026     2025  
Total inside merchandise sales   $ 246,449   $ 236,925     $ 700,231   $ 662,107  
Same-store inside merchandise sales     1.9 %   1.6 %     2.4 %   1.3 %
Inside Merchandise Gross Profit   $ 86,557   $ 83,376     $ 249,499   $ 231,065  
Inside merchandise margin     35.1 %   35.2 %     35.6 %   34.9 %
                             

Adjusted EBITDA

Adjusted EBITDA increased 8.6% year-over-year to $59.6 million, primarily attributable to the increase in fuel margin cents per gallon and inside merchandise margin from same-store sales and increases in fuel gallons and inside merchandise sales from new stores, partially offset by higher operating expenses primarily attributable to higher interchange fees related to higher revenue.

A reconciliation of net income to Adjusted EBITDA, a non-GAAP financial measure, is provided in the tables below.

Store Contribution

Store Contribution increased 9.2% year-over-year to $77.0 million, primarily attributable to the increase in fuel margin cents per gallon and inside merchandise margin from same-store sales and increases in fuel gallons and inside merchandise sales from new stores, partially offset by higher operating expenses primarily attributable to higher interchange fees related to higher revenue.

A reconciliation of income from operations to Store Contribution, a non-GAAP financial measure, is provided in the tables below.

Store Count

As of September 30, 2026, the Company operated 423 stores under the Yesway and Allsup’s brands. The following table represents the roll forward of store count through the third quarter of fiscal 2026.

Stores, beginning of period   448  
Opened   4  
Sold(1)   (29 )
Stores, end of period   423  
       
  1. Results for the periods above include 29 stores in Iowa and Kansas, which were sold in September 2026. Excluding these 29 locations, our store portfolio as of September 30, 2026, consisted of 423 stores, including 422 convenience stores and one liquor store.

Balance Sheet, Cash Flow and Liquidity

As of September 30, 2026, the Company had cash and cash equivalents of $104.6 million and total debt, including financing obligations and finance lease obligations, of $607.9 million.

Net cash provided by operating activities was $66.1 million for the three months ended September 30, 2026, compared to $54.2 million in the prior-year period.

Capital expenditures totaled $36.7 million for the three months ended September 30, 2026, compared to $11.3 million in the prior-year period.

Full Year 2026 Outlook

The Company has reaffirmed its outlook for the following metrics as detailed below:

   
Adjusted EBITDA   $235 million – $245 million
Same-store Inside Merchandise Sales Growth   1.25% – 3.25%
Capital Expenditures   $85 million – $95 million
New Store Openings   6 – 8 new stores
     

Conference Call Details

Yesway will hold a conference call and webcast to discuss its third quarter 2026 financial results today, Thursday, November 12, 2026, at 8:30 AM ET.

A live webcast of the conference call will be available on the Investor Relations section of the Company’s website or by clicking on the webcast link here. An online archive of the webcast will be available on the Company’s website for one year following the call.

About Yesway

Established in 2015 and headquartered in Fort Worth, TX, Yesway is an award-winning convenience store operator with approximately 420 stores across eight states in the Midwest and Southwest. Yesway is renowned for its iconic foodservice offerings, diverse grocery selections, and private-label products, including the famous Allsup’s deep-fried burrito. Through strategic acquisitions, the development and opening of more than 90 stores over the past several years, and a steadfast commitment to customer satisfaction and community engagement, Yesway continues to cement its position as one of the leading convenience retailers in the United States.

Non-GAAP Financial Measures

We use non-GAAP financial measures, such as Adjusted EBITDA and Store Contribution, to supplement financial information presented in accordance with GAAP. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance, in the case of Adjusted EBITDA, and the direct performance of our stores, in the case of Store Contribution, from period to period, and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented herein. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Additionally, Store Contribution excludes costs that we incur on an enterprise level that while essential in supporting our store operations, are not directly related to store operations, and that we believe result in efficiencies of scale and confer other benefits across our business. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

A reconciliation of our guidance contained in this press release of Adjusted EBITDA to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including but not limited to, uncertainty related to the timing, amount, and structure of stock-based compensation awards, as well as potential forfeitures of such awards, all of which could materially impact the Company’s estimates of forward-looking GAAP net income. These items are inherently difficult to predict, subject to significant variability, and dependent on factors that may be outside of the Company’s control.

See “Definitions” for additional information about our non-GAAP financial measures and “Non-GAAP Reconciling Information” for a reconciliation for each non-GAAP financial measure to the most directly comparable GAAP financial measure.

Definitions

  • We define the same-store base for a given period as all owned or leased stores that were open for the entirety of that period in both the current and prior years. This measure highlights the performance of existing stores, while excluding the impact of new store openings and closures as well as acquisitions and divestitures.
  • We define gross profit as sales less cost of goods sold (exclusive of depreciation and amortization).
  • Store Contribution represents, as applicable for the period, income (loss) from operations before depreciation, amortization and accretion, loss (gain) on disposal of assets, long-lived asset impairment, acquisition, financing, integration, and stock-based compensation expense, and overhead expenses directly attributed to support staff and corporate offices that, while essential in supporting our store operations, are not directly related to store operations. 
  • Adjusted EBITDA represents, as applicable for the period, net income (loss) before change in fair value of derivative liability, impairment on equity investment, interest expense, net, income tax expense, depreciation, amortization, and accretion, (gain) loss on disposal of assets, goodwill impairment, long-lived asset impairment, acquisition, financing, and integration costs, and equity-based compensation.

Presentation of Financial Information

As a result of Yesway’s initial public offering in April 2026, Yesway now consolidates the results of BW Ultimate Parent, LLC, for financial reporting purposes. All of Yesway’s business operations are currently, and have historically been, conducted through BW Ultimate Parent, LLC and its subsidiaries. Periods prior to Yesway’s initial public offering reflect the results of BW Ultimate Parent, LLC.

Cautionary Note Regarding Forward-looking Statements

Some information in this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, 2026 guidance, including with respect to same-store inside merchandise sales growth, Adjusted EBITDA, capital expenditures and new store openings, expected growth and future capital expenditures, execution of our growth priorities and creation of long-term value, are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as “may,” “will,” “would,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: volatility in the global prices and availability of oil and petroleum products and general economic conditions, including interest rates; our ability to maintain an adequate pipeline of suitable locations for new stores; our ability to successfully implement our rapid growth strategy; risks associated with new store development; our ability to successfully recruit, hire, and retain qualified personnel; our dependence upon market acceptance by consumers and our failure to offer products that meet our existing customers’ taste and attract new customers; changes to wage regulations and other employment and labor laws; changes in demand for fuel-based modes of transportation and advancements in technologies, such as hybrid and electric vehicles, that significantly reduce fuel consumption related to the public’s current general approach with regard to climate change and the effects of greenhouse gas emissions, among others; our dependence on a limited number of suppliers for the majority of our gross fuel purchases and merchandise; operational hazards and risks normally associated with marketing of petroleum products; hazards and risks relating to the physical effects of weather and climate change; changes to tobacco legislation, potential court rulings affecting the tobacco industry, campaigns to discourage smoking, increases in tobacco and nicotine products taxes and wholesale cost increases of tobacco and nicotine products; the significant influence that Brookwood Financial Partners, LLC continues to have over us, including control over decisions that require the approval of stockholders; and the other important factors discussed under “Risk Factors” in our final prospectus dated April 21, 2026, as filed with the SEC on April 23, 2026 pursuant to Rule 424(b) under the Securities Act of 1933 (the “Prospectus”) and in our other filings with the SEC.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release. If one or more events related to these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Investor Contact:
IR@yesway.com

Media Contact:
Erin Vadala
evadala@boltpr.com

Yesway, Inc. and Subsidiaries
Condensed Consolidated Statements of Income (Unaudited)
(dollars in thousands, except per share amounts)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026     2025     2026     2025  
Revenues (a)   $ 969,153     $ 715,885     $ 2,573,557     $ 1,993,876  
                         
Expenses:                        
Cost of goods sold (exclusive of depreciation and amortization, shown separately below) (a)     797,392       560,660       2,070,080       1,569,280  
Salaries and employee benefits     59,140       50,645       164,469       149,773  
Selling, general, and administrative expenses     60,733       53,301       163,902       147,596  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Goodwill impairment     —       1,390       —       1,390  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Total operating expenses     930,402       680,441       2,444,618       1,911,500  
Income from operations     38,751       35,444       128,939       82,376  
Other expense (income):                        
Interest expense, net     11,363       14,376       35,464       43,426  
Impairment on equity investment     —       5,260       —       5,260  
Change in fair value of derivative liability     —       (100 )     —       (900 )
Total other expense, net     11,363       19,536       35,464       47,786  
Income before income tax expense     27,388       15,908       93,475       34,590  
Income tax expense     2,593       5       8,790       163  
Net income     24,795       15,903       84,685       34,427  
                         
Net income attributable to non-controlling interest     13,950       41       27,313       41  
Net income attributable to Yesway, Inc. and subsidiaries   $ 10,845     $ 15,862     $ 57,372     $ 34,386  
                         
(a) Includes excise taxes of:   $ 67,770     $ 63,854     $ 193,053     $ 178,913  
                         
    Three Months
Ended
September 30,
2026
        Period from
April 23, 2026,
to
September 30,
2026
     
Earnings per share of Class A common stock:                        
Basic   $ 0.35           $ 0.56        
Diluted   $ 0.34           $ 0.56        
                         
Weighted-average shares of Class A common stock:                        
Basic     31,185,561             31,133,387        
Diluted     63,399,726             31,324,646        
                             

Yesway, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
(dollars in thousands)
         
    September 30, 2026   December 31, 2025
Assets            
Current assets:            
Cash and cash equivalents   $ 104,572   $ 36,592
Accounts receivable, net of allowance for credit losses of $138 and $147 as of September 30, 2026, and December 31, 2025, respectively     53,536     24,538
Inventories     98,181     83,171
Prepaid expenses     4,250     6,158
Other current assets     16,573     13,235
Total current assets     277,112     163,694
             
Property and equipment, net     886,510     868,559
Intangible assets     283,068     280,946
Goodwill     277,996     277,996
Operating lease right-of-use assets, net     339,665     332,655
Finance lease right-of-use assets, net     1,845     1,931
Assets held for sale     —     16,501
Deferred tax assets     33,581     —
Other assets     10,244     6,892
Total assets   $ 2,110,021   $ 1,949,174

Liabilities, redeemable senior preferred membership interests, and stockholders’/members’ equity            
Current liabilities:            
Current maturities of debt     4,100     4,100
Current maturities of financing obligations     2,130     2,034
Current maturities of operating lease liabilities     5,848     5,417
Current maturities of finance lease liabilities     71     68
Due to affiliates     153     46
Accounts payable     120,293     72,964
Accrued expenses and other current liabilities     51,973     49,072
Total current liabilities   $ 184,568   $ 133,701
             
Debt, net of current maturities, debt discount, and debt issuance costs     378,162     428,211
Financing obligations, net of current maturities, debt discount, and debt issuance costs     221,290     222,851
Operating lease liabilities, net of current maturities     326,441     316,451
Finance lease liabilities, net of current maturities     2,125     2,180
Asset retirement obligations     10,516     10,096
Liabilities held for sale     —     1,422
Tax receivable agreement liability     92,263     —
Other noncurrent liabilities     9,973     11,465
Total liabilities   $ 1,225,338   $ 1,126,377
             
Commitments and contingencies            
             
Redeemable senior preferred membership interests (0 and 150,000 shares authorized and outstanding, redemption value of $0 and $239,628 and liquidation preference amount of $0 and $239,628 as of September 30, 2026, and December 31, 2025, respectively)     —     239,628
             
Stockholders’/members’ equity            
Members’ equity     —     582,070
Class A common stock, $0.0001 par value, 500,000,000 shares authorized, 31,185,561 issued and outstanding     3     —
Class B common stock, $0.0001 par value, 150,000,000 shares authorized, 32,009,185 issued and outstanding     3     —
Additional paid-in capital     394,457     —
Retained earnings     17,419     —
Total stockholders’ equity attributable to Yesway, Inc./members’ equity     411,882     582,070
Non-controlling interests     472,801     1,099
Total stockholders’/members’ equity     884,683     583,169
Total liabilities, redeemable senior preferred membership interests, stockholders’ equity/members’ equity   $ 2,110,021   $ 1,949,174
             

Yesway, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(dollars in thousands)
             
Nine months ended September 30,    2026     2025  
Cash flows from operating activities            
Net income   $ 84,685     $ 34,427  
Adjustments to reconcile net income to net cash provided by operating activities:            
Depreciation, amortization, and accretion     49,866       45,922  
Amortization of right-of-use assets     9,182       6,558  
Amortization of deferred financing cost     3,233       3,204  
Allowance for credit losses     9       10  
Gain on disposal of assets     (3,699 )     (2,461 )
Equity-based compensation     11,045       —  
Deferred income tax     8,046       —  
Change in fair value of derivative liability     —       (900 )
Impairment on equity investment     —       5,260  
Goodwill impairment     —       1,390  
Changes in operating assets and liabilities, net            
Accounts receivables     (15,225 )     (7,282 )
Inventories     (18,563 )     (1,423 )
Prepaid expenses     1,908       642  
Other current assets – BTS     (2,676 )     —  
Other current assets – Other     (662 )     (298 )
Accounts payable – Fuel     44,191       10,852  
Accounts payable – Other     2,513       1,758  
Accrued expenses and other current liabilities     2,551       9,171  
Lease liabilities     (3,934 )     (3,402 )
Other noncurrent liabilities     (1,572 )     —  
Due to/(from) affiliates     106       —  
Net cash provided by operating activities     171,004       103,428  
             
Cash flows from investing activities            
Purchase of property and equipment     (71,813 )     (59,487 )
Acquisition of intangible assets     (2,123 )     (2,829 )
Proceeds from sale of assets     8,152       4,435  
Other investing activities     (2,829 )     (309 )
Net cash used in investing activities     (68,613 )     (58,190 )
             
Cash flows from financing activities            
Proceeds from revolver     —       15,000  
Repayment of revolver     (50,000 )     (35,000 )
Repayment of borrowings from term loan     (3,075 )     (3,075 )
Cash paid for debt issuance costs     (110 )     (608 )
Proceeds from financing obligation     2,489       4,977  
Repayment of financing obligation with lessors     (1,555 )     (1,554 )
Repayment of financing leases     (51 )     (48 )
Proceeds from issuance of common stock     301,070       —  
Cash paid for IPO issuance costs     (7,403 )     —  
Distributions to redeemable senior preferred membership interests     (252,266 )     (579 )
Distributions to members     (23,510 )     (9,193 )
Net cash used in financing activities     (34,411 )     (30,080 )
             
Increase (decrease) in cash and cash equivalents     67,980       15,158  
             
Cash and cash equivalents, beginning of period     36,592       32,720  
             
Cash and cash equivalents, end of period   $ 104,572     $ 47,878  
                 

Non-GAAP Reconciling Information

The following table contains a reconciliation of net income to Adjusted EBITDA for the three and nine months ended September 30, 2026, and 2025, respectively:

Yesway, Inc. and Subsidiaries
Reconciliation of Net Income to Adjusted EBITDA
(dollars in thousands)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026   2025   2026   2025
Net income (loss)   $ 24,795     $ 15,903     $ 84,685     $ 34,427  
Change in fair value of derivative liability     —       (100 )     —       (900 )
Impairment on equity investment     —       5,260       —       5,260  
Interest expense, net     11,363       14,376       35,464       43,426  
Income tax expense     2,593       5       8,790       163  
Income from operations     38,751       35,444       128,939       82,376  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Goodwill impairment     —       1,390       —       1,390  
Acquisition, financing, and integration costs     1,380       3,627       3,545       7,952  
Equity-based compensation     6,337       —       11,045       —  
Adjusted EBITDA   $ 59,605     $ 54,906     $ 189,696     $ 135,179  
                                 

The following table contains a reconciliation of income from operations to Store Contribution for the three and nine months ended September 30, 2026, and 2025, respectively:

Yesway, Inc. and Subsidiaries
Reconciliation of Income from Operations to Store Contribution
(dollars in thousands)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026   2025   2026   2025
Income from operations   $ 38,751     $ 35,444     $ 128,939     $ 82,376  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Goodwill impairment     —       1,390       —       1,390  
Acquisition, financing, and integration costs     1,380       3,627       3,545       7,952  
Overhead expenses:                        
Salaries and benefits     11,263       10,444       33,151       31,965  
Facility expenses     276       280       827       753  
Professional services     2,094       2,130       5,555       5,533  
Marketing and advertising     907       1,018       2,675       2,795  
Computer software and hardware     1,054       611       2,423       1,921  
Office supplies     40       22       98       64  
Repairs and maintenance     399       184       958       530  
Meetings and travel     790       580       2,337       1,346  
Insurance     500       249       1,133       706  
Other expense     80       73       482       576  
Equity-based compensation     6,337       —       11,045       —  
Total overhead expenses     23,740       15,591       60,684       46,189  
Store Contribution (1)   $ 77,008     $ 70,497     $ 239,335     $ 181,368  
                                 
  1. Store Contribution generated by the 29 stores in Iowa and Kansas was $304 thousand and $932 thousand in the three and nine months ended September 30, 2026, respectively, and $304 thousand and $947 thousand in the three and nine months ended September 30, 2025, respectively.

Delivered same-store inside merchandise sales growth in 19 of the past 20 quarters and positive same-store fuel gallons growth for the fifth consecutive quarter

Opened two new stores in the third quarter, including first Arizona location

Reaffirmed full year 2026 outlook, reflecting continued momentum across the business

FORT WORTH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Yesway, Inc. (“Yesway” or the “Company”) (Nasdaq: YSWY), one of the fastest-growing convenience store operators in the United States, today announced financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights

  • Net income increased to $24.8 million from $15.9 million in the prior-year period, and Adjusted EBITDA increased 8.6% year-over-year to $59.6 million.
  • Same-store inside merchandise sales increased 1.9% year-over-year. Total inside merchandise sales increased 4.0% year-over-year, with a total inside merchandise margin of 35.1%.
  • Same-store fuel gallons sold increased 1.1% year-over-year. Total fuel gallons sold increased 4.8% year-over-year, with a total fuel margin of 46.1 cents per gallon.
  • Income from operations increased to $38.8 million from $35.4 million in the prior-year period, and Store Contribution increased 9.2% year-over-year to $77.0 million.

“We delivered another exceptional quarter, building on our strong performance in the first half of 2026,” said Thomas N. Trkla, Chairman, President and Chief Executive Officer of Yesway. “We continued to grow inside merchandise sales and fuel gallons, expand our market share, and deliver strong profitability against a challenging consumer environment. This continued momentum reflects our differentiated market positioning, deliberate geographic focus, significant diesel exposure, and destination foodservice platform.”

Mr. Trkla continued, “We are proud of what our team has accomplished and excited for what is ahead for Yesway as we continue to advance our three growth priorities – new store development, initiatives that strengthen our existing operations, and selective acquisitions – and drive long-term value for all our stakeholders.”

Third Quarter Results

Same-Store Comparison

Total fuel and inside merchandise gross profit increased 7.9% year-over-year on a same-store basis, reflecting growth in both fuel and inside merchandise categories.

Fuel gallons sold increased 1.1% year-over-year on a same-store basis, and same-store fuel gross profit increased 16.4% year-over-year.

Inside merchandise sales increased 1.9% year-over-year on a same-store basis, and same-store inside merchandise gross profit increased 1.4% year-over-year.

    Three months
ended September 30,
  Nine months
ended September 30,
Same-Store Year-Over-Year Comparison by Category (1)   2026 2025   2026 2025
Fuel Gallons   1.1 % 2.7 %   0.9 % 0.1 %
Fuel Gross Profit (2)   16.4 % 3.5 %   26.6 % 1.2 %
Inside Merchandise Sales   1.9 % 1.6 %   2.4 % 1.3 %
Inside Merchandise Gross Profit (3)   1.4 % 6.3 %   4.3 % 6.1 %
Total Fuel and Inside Merchandise Gross Profit   7.9 % 5.1 %   13.8 % 4.0 %
                     
  1. Same-store calculations for the current quarter and year-to-date periods ended September 30, 2026, exclude Iowa and Kansas locations that ceased operations prior to the end of the third quarter.
  2. Defined as fuel sales less cost of goods sold (exclusive of depreciation and amortization).
  3. Defined as inside merchandise sales less cost of goods sold (exclusive of depreciation and amortization).

Fuel

Fuel sales increased 51.6% year-over-year to $713.5 million, and fuel gross profit increased 19.8% year-over-year to $76.0 million, primarily driven by an increase in fuel margin cents per gallon, which increased 14.4% year-over-year to 46.1 cents per gallon, as well as increased fuel volumes.

 

  Three months
ended September 30,
  Nine months
ended September 30,
Fuel ($ in thousands)     2026     2025       2026     2025  
Fuel gallons sold (in thousands)     164,713     157,101       469,334     440,712  
Same-store gallons sold     1.1 %   2.7 %     0.9 %   0.1 %
Fuel Gross Profit   $ 75,972   $ 63,389     $ 231,565   $ 173,261  
Fuel Margin (cents per gallon)     46.1     40.3       49.3     39.3  
                             

Inside Merchandise

Inside merchandise sales increased 4.0% year-over-year to $246.4 million, and inside merchandise gross profit increased 3.8% year-over-year to $86.6 million, primarily driven by incremental sales resulting from a higher concentration of new stores, as well as pricing actions taken during 2026 and late 2025.

    Three months
ended September 30,
  Nine months
ended September 30,
Inside Merchandise ($ in thousands)     2026     2025       2026     2025  
Total inside merchandise sales   $ 246,449   $ 236,925     $ 700,231   $ 662,107  
Same-store inside merchandise sales     1.9 %   1.6 %     2.4 %   1.3 %
Inside Merchandise Gross Profit   $ 86,557   $ 83,376     $ 249,499   $ 231,065  
Inside merchandise margin     35.1 %   35.2 %     35.6 %   34.9 %
                             

Adjusted EBITDA

Adjusted EBITDA increased 8.6% year-over-year to $59.6 million, primarily attributable to the increase in fuel margin cents per gallon and inside merchandise margin from same-store sales and increases in fuel gallons and inside merchandise sales from new stores, partially offset by higher operating expenses primarily attributable to higher interchange fees related to higher revenue.

A reconciliation of net income to Adjusted EBITDA, a non-GAAP financial measure, is provided in the tables below.

Store Contribution

Store Contribution increased 9.2% year-over-year to $77.0 million, primarily attributable to the increase in fuel margin cents per gallon and inside merchandise margin from same-store sales and increases in fuel gallons and inside merchandise sales from new stores, partially offset by higher operating expenses primarily attributable to higher interchange fees related to higher revenue.

A reconciliation of income from operations to Store Contribution, a non-GAAP financial measure, is provided in the tables below.

Store Count

As of September 30, 2026, the Company operated 423 stores under the Yesway and Allsup’s brands. The following table represents the roll forward of store count through the third quarter of fiscal 2026.

Stores, beginning of period   448  
Opened   4  
Sold(1)   (29 )
Stores, end of period   423  
       
  1. Results for the periods above include 29 stores in Iowa and Kansas, which were sold in September 2026. Excluding these 29 locations, our store portfolio as of September 30, 2026, consisted of 423 stores, including 422 convenience stores and one liquor store.

Balance Sheet, Cash Flow and Liquidity

As of September 30, 2026, the Company had cash and cash equivalents of $104.6 million and total debt, including financing obligations and finance lease obligations, of $607.9 million.

Net cash provided by operating activities was $66.1 million for the three months ended September 30, 2026, compared to $54.2 million in the prior-year period.

Capital expenditures totaled $36.7 million for the three months ended September 30, 2026, compared to $11.3 million in the prior-year period.

Full Year 2026 Outlook

The Company has reaffirmed its outlook for the following metrics as detailed below:

   
Adjusted EBITDA   $235 million – $245 million
Same-store Inside Merchandise Sales Growth   1.25% – 3.25%
Capital Expenditures   $85 million – $95 million
New Store Openings   6 – 8 new stores
     

Conference Call Details

Yesway will hold a conference call and webcast to discuss its third quarter 2026 financial results today, Thursday, November 12, 2026, at 8:30 AM ET.

A live webcast of the conference call will be available on the Investor Relations section of the Company’s website or by clicking on the webcast link here. An online archive of the webcast will be available on the Company’s website for one year following the call.

About Yesway

Established in 2015 and headquartered in Fort Worth, TX, Yesway is an award-winning convenience store operator with approximately 420 stores across eight states in the Midwest and Southwest. Yesway is renowned for its iconic foodservice offerings, diverse grocery selections, and private-label products, including the famous Allsup’s deep-fried burrito. Through strategic acquisitions, the development and opening of more than 90 stores over the past several years, and a steadfast commitment to customer satisfaction and community engagement, Yesway continues to cement its position as one of the leading convenience retailers in the United States.

Non-GAAP Financial Measures

We use non-GAAP financial measures, such as Adjusted EBITDA and Store Contribution, to supplement financial information presented in accordance with GAAP. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance, in the case of Adjusted EBITDA, and the direct performance of our stores, in the case of Store Contribution, from period to period, and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented herein. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Additionally, Store Contribution excludes costs that we incur on an enterprise level that while essential in supporting our store operations, are not directly related to store operations, and that we believe result in efficiencies of scale and confer other benefits across our business. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

A reconciliation of our guidance contained in this press release of Adjusted EBITDA to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including but not limited to, uncertainty related to the timing, amount, and structure of stock-based compensation awards, as well as potential forfeitures of such awards, all of which could materially impact the Company’s estimates of forward-looking GAAP net income. These items are inherently difficult to predict, subject to significant variability, and dependent on factors that may be outside of the Company’s control.

See “Definitions” for additional information about our non-GAAP financial measures and “Non-GAAP Reconciling Information” for a reconciliation for each non-GAAP financial measure to the most directly comparable GAAP financial measure.

Definitions

  • We define the same-store base for a given period as all owned or leased stores that were open for the entirety of that period in both the current and prior years. This measure highlights the performance of existing stores, while excluding the impact of new store openings and closures as well as acquisitions and divestitures.
  • We define gross profit as sales less cost of goods sold (exclusive of depreciation and amortization).
  • Store Contribution represents, as applicable for the period, income (loss) from operations before depreciation, amortization and accretion, loss (gain) on disposal of assets, long-lived asset impairment, acquisition, financing, integration, and stock-based compensation expense, and overhead expenses directly attributed to support staff and corporate offices that, while essential in supporting our store operations, are not directly related to store operations. 
  • Adjusted EBITDA represents, as applicable for the period, net income (loss) before change in fair value of derivative liability, impairment on equity investment, interest expense, net, income tax expense, depreciation, amortization, and accretion, (gain) loss on disposal of assets, goodwill impairment, long-lived asset impairment, acquisition, financing, and integration costs, and equity-based compensation.

Presentation of Financial Information

As a result of Yesway’s initial public offering in April 2026, Yesway now consolidates the results of BW Ultimate Parent, LLC, for financial reporting purposes. All of Yesway’s business operations are currently, and have historically been, conducted through BW Ultimate Parent, LLC and its subsidiaries. Periods prior to Yesway’s initial public offering reflect the results of BW Ultimate Parent, LLC.

Cautionary Note Regarding Forward-looking Statements

Some information in this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, 2026 guidance, including with respect to same-store inside merchandise sales growth, Adjusted EBITDA, capital expenditures and new store openings, expected growth and future capital expenditures, execution of our growth priorities and creation of long-term value, are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as “may,” “will,” “would,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: volatility in the global prices and availability of oil and petroleum products and general economic conditions, including interest rates; our ability to maintain an adequate pipeline of suitable locations for new stores; our ability to successfully implement our rapid growth strategy; risks associated with new store development; our ability to successfully recruit, hire, and retain qualified personnel; our dependence upon market acceptance by consumers and our failure to offer products that meet our existing customers’ taste and attract new customers; changes to wage regulations and other employment and labor laws; changes in demand for fuel-based modes of transportation and advancements in technologies, such as hybrid and electric vehicles, that significantly reduce fuel consumption related to the public’s current general approach with regard to climate change and the effects of greenhouse gas emissions, among others; our dependence on a limited number of suppliers for the majority of our gross fuel purchases and merchandise; operational hazards and risks normally associated with marketing of petroleum products; hazards and risks relating to the physical effects of weather and climate change; changes to tobacco legislation, potential court rulings affecting the tobacco industry, campaigns to discourage smoking, increases in tobacco and nicotine products taxes and wholesale cost increases of tobacco and nicotine products; the significant influence that Brookwood Financial Partners, LLC continues to have over us, including control over decisions that require the approval of stockholders; and the other important factors discussed under “Risk Factors” in our final prospectus dated April 21, 2026, as filed with the SEC on April 23, 2026 pursuant to Rule 424(b) under the Securities Act of 1933 (the “Prospectus”) and in our other filings with the SEC.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release. If one or more events related to these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Investor Contact:
IR@yesway.com

Media Contact:
Erin Vadala
evadala@boltpr.com

Yesway, Inc. and Subsidiaries
Condensed Consolidated Statements of Income (Unaudited)
(dollars in thousands, except per share amounts)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026     2025     2026     2025  
Revenues (a)   $ 969,153     $ 715,885     $ 2,573,557     $ 1,993,876  
                         
Expenses:                        
Cost of goods sold (exclusive of depreciation and amortization, shown separately below) (a)     797,392       560,660       2,070,080       1,569,280  
Salaries and employee benefits     59,140       50,645       164,469       149,773  
Selling, general, and administrative expenses     60,733       53,301       163,902       147,596  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Goodwill impairment     —       1,390       —       1,390  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Total operating expenses     930,402       680,441       2,444,618       1,911,500  
Income from operations     38,751       35,444       128,939       82,376  
Other expense (income):                        
Interest expense, net     11,363       14,376       35,464       43,426  
Impairment on equity investment     —       5,260       —       5,260  
Change in fair value of derivative liability     —       (100 )     —       (900 )
Total other expense, net     11,363       19,536       35,464       47,786  
Income before income tax expense     27,388       15,908       93,475       34,590  
Income tax expense     2,593       5       8,790       163  
Net income     24,795       15,903       84,685       34,427  
                         
Net income attributable to non-controlling interest     13,950       41       27,313       41  
Net income attributable to Yesway, Inc. and subsidiaries   $ 10,845     $ 15,862     $ 57,372     $ 34,386  
                         
(a) Includes excise taxes of:   $ 67,770     $ 63,854     $ 193,053     $ 178,913  
                         
    Three Months
Ended
September 30,
2026
        Period from
April 23, 2026,
to
September 30,
2026
     
Earnings per share of Class A common stock:                        
Basic   $ 0.35           $ 0.56        
Diluted   $ 0.34           $ 0.56        
                         
Weighted-average shares of Class A common stock:                        
Basic     31,185,561             31,133,387        
Diluted     63,399,726             31,324,646        
                             

Yesway, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
(dollars in thousands)
         
    September 30, 2026   December 31, 2025
Assets            
Current assets:            
Cash and cash equivalents   $ 104,572   $ 36,592
Accounts receivable, net of allowance for credit losses of $138 and $147 as of September 30, 2026, and December 31, 2025, respectively     53,536     24,538
Inventories     98,181     83,171
Prepaid expenses     4,250     6,158
Other current assets     16,573     13,235
Total current assets     277,112     163,694
             
Property and equipment, net     886,510     868,559
Intangible assets     283,068     280,946
Goodwill     277,996     277,996
Operating lease right-of-use assets, net     339,665     332,655
Finance lease right-of-use assets, net     1,845     1,931
Assets held for sale     —     16,501
Deferred tax assets     33,581     —
Other assets     10,244     6,892
Total assets   $ 2,110,021   $ 1,949,174

Liabilities, redeemable senior preferred membership interests, and stockholders’/members’ equity            
Current liabilities:            
Current maturities of debt     4,100     4,100
Current maturities of financing obligations     2,130     2,034
Current maturities of operating lease liabilities     5,848     5,417
Current maturities of finance lease liabilities     71     68
Due to affiliates     153     46
Accounts payable     120,293     72,964
Accrued expenses and other current liabilities     51,973     49,072
Total current liabilities   $ 184,568   $ 133,701
             
Debt, net of current maturities, debt discount, and debt issuance costs     378,162     428,211
Financing obligations, net of current maturities, debt discount, and debt issuance costs     221,290     222,851
Operating lease liabilities, net of current maturities     326,441     316,451
Finance lease liabilities, net of current maturities     2,125     2,180
Asset retirement obligations     10,516     10,096
Liabilities held for sale     —     1,422
Tax receivable agreement liability     92,263     —
Other noncurrent liabilities     9,973     11,465
Total liabilities   $ 1,225,338   $ 1,126,377
             
Commitments and contingencies            
             
Redeemable senior preferred membership interests (0 and 150,000 shares authorized and outstanding, redemption value of $0 and $239,628 and liquidation preference amount of $0 and $239,628 as of September 30, 2026, and December 31, 2025, respectively)     —     239,628
             
Stockholders’/members’ equity            
Members’ equity     —     582,070
Class A common stock, $0.0001 par value, 500,000,000 shares authorized, 31,185,561 issued and outstanding     3     —
Class B common stock, $0.0001 par value, 150,000,000 shares authorized, 32,009,185 issued and outstanding     3     —
Additional paid-in capital     394,457     —
Retained earnings     17,419     —
Total stockholders’ equity attributable to Yesway, Inc./members’ equity     411,882     582,070
Non-controlling interests     472,801     1,099
Total stockholders’/members’ equity     884,683     583,169
Total liabilities, redeemable senior preferred membership interests, stockholders’ equity/members’ equity   $ 2,110,021   $ 1,949,174
             

Yesway, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(dollars in thousands)
             
Nine months ended September 30,    2026     2025  
Cash flows from operating activities            
Net income   $ 84,685     $ 34,427  
Adjustments to reconcile net income to net cash provided by operating activities:            
Depreciation, amortization, and accretion     49,866       45,922  
Amortization of right-of-use assets     9,182       6,558  
Amortization of deferred financing cost     3,233       3,204  
Allowance for credit losses     9       10  
Gain on disposal of assets     (3,699 )     (2,461 )
Equity-based compensation     11,045       —  
Deferred income tax     8,046       —  
Change in fair value of derivative liability     —       (900 )
Impairment on equity investment     —       5,260  
Goodwill impairment     —       1,390  
Changes in operating assets and liabilities, net            
Accounts receivables     (15,225 )     (7,282 )
Inventories     (18,563 )     (1,423 )
Prepaid expenses     1,908       642  
Other current assets – BTS     (2,676 )     —  
Other current assets – Other     (662 )     (298 )
Accounts payable – Fuel     44,191       10,852  
Accounts payable – Other     2,513       1,758  
Accrued expenses and other current liabilities     2,551       9,171  
Lease liabilities     (3,934 )     (3,402 )
Other noncurrent liabilities     (1,572 )     —  
Due to/(from) affiliates     106       —  
Net cash provided by operating activities     171,004       103,428  
             
Cash flows from investing activities            
Purchase of property and equipment     (71,813 )     (59,487 )
Acquisition of intangible assets     (2,123 )     (2,829 )
Proceeds from sale of assets     8,152       4,435  
Other investing activities     (2,829 )     (309 )
Net cash used in investing activities     (68,613 )     (58,190 )
             
Cash flows from financing activities            
Proceeds from revolver     —       15,000  
Repayment of revolver     (50,000 )     (35,000 )
Repayment of borrowings from term loan     (3,075 )     (3,075 )
Cash paid for debt issuance costs     (110 )     (608 )
Proceeds from financing obligation     2,489       4,977  
Repayment of financing obligation with lessors     (1,555 )     (1,554 )
Repayment of financing leases     (51 )     (48 )
Proceeds from issuance of common stock     301,070       —  
Cash paid for IPO issuance costs     (7,403 )     —  
Distributions to redeemable senior preferred membership interests     (252,266 )     (579 )
Distributions to members     (23,510 )     (9,193 )
Net cash used in financing activities     (34,411 )     (30,080 )
             
Increase (decrease) in cash and cash equivalents     67,980       15,158  
             
Cash and cash equivalents, beginning of period     36,592       32,720  
             
Cash and cash equivalents, end of period   $ 104,572     $ 47,878  
                 

Non-GAAP Reconciling Information

The following table contains a reconciliation of net income to Adjusted EBITDA for the three and nine months ended September 30, 2026, and 2025, respectively:

Yesway, Inc. and Subsidiaries
Reconciliation of Net Income to Adjusted EBITDA
(dollars in thousands)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026   2025   2026   2025
Net income (loss)   $ 24,795     $ 15,903     $ 84,685     $ 34,427  
Change in fair value of derivative liability     —       (100 )     —       (900 )
Impairment on equity investment     —       5,260       —       5,260  
Interest expense, net     11,363       14,376       35,464       43,426  
Income tax expense     2,593       5       8,790       163  
Income from operations     38,751       35,444       128,939       82,376  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Goodwill impairment     —       1,390       —       1,390  
Acquisition, financing, and integration costs     1,380       3,627       3,545       7,952  
Equity-based compensation     6,337       —       11,045       —  
Adjusted EBITDA   $ 59,605     $ 54,906     $ 189,696     $ 135,179  
                                 

The following table contains a reconciliation of income from operations to Store Contribution for the three and nine months ended September 30, 2026, and 2025, respectively:

Yesway, Inc. and Subsidiaries
Reconciliation of Income from Operations to Store Contribution
(dollars in thousands)
         
    Three Months Ended   Nine Months Ended
    September 30,    September 30, 
    2026   2025   2026   2025
Income from operations   $ 38,751     $ 35,444     $ 128,939     $ 82,376  
Depreciation, amortization, and accretion     17,257       14,715       49,866       45,922  
Gain on disposal of assets     (4,120 )     (270 )     (3,699 )     (2,461 )
Goodwill impairment     —       1,390       —       1,390  
Acquisition, financing, and integration costs     1,380       3,627       3,545       7,952  
Overhead expenses:                        
Salaries and benefits     11,263       10,444       33,151       31,965  
Facility expenses     276       280       827       753  
Professional services     2,094       2,130       5,555       5,533  
Marketing and advertising     907       1,018       2,675       2,795  
Computer software and hardware     1,054       611       2,423       1,921  
Office supplies     40       22       98       64  
Repairs and maintenance     399       184       958       530  
Meetings and travel     790       580       2,337       1,346  
Insurance     500       249       1,133       706  
Other expense     80       73       482       576  
Equity-based compensation     6,337       —       11,045       —  
Total overhead expenses     23,740       15,591       60,684       46,189  
Store Contribution (1)   $ 77,008     $ 70,497     $ 239,335     $ 181,368  
                                 
  1. Store Contribution generated by the 29 stores in Iowa and Kansas was $304 thousand and $932 thousand in the three and nine months ended September 30, 2026, respectively, and $304 thousand and $947 thousand in the three and nine months ended September 30, 2025, respectively.

COSTA MESA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) a global supplier of Engineered Products, Aftermarket and Value-Added Manufacturing Solutions for the aerospace and defense industry, is proud to announce that Chairman, President and Chief Executive Officer Stephen G. Oswald and his wife, Regina, were honored with the Taking Action Award at the Orange County United Way (OCUW) Annual Gala on November 7, 2026, in Laguna Niguel, California.

The Taking Action Award recognizes individuals whose generosity, leadership, and commitment to philanthropy create meaningful and lasting change in their communities. Steve and Regina were recognized for their longstanding dedication to giving back, their personal involvement in charitable initiatives, and their commitment to making a positive difference in the lives of others. Ducommun was also proud to serve as the Title Sponsor of this year’s gala, demonstrating the Company’s continued commitment to supporting the communities where its employees live and work.

“We are truly honored and humbled to receive this recognition from Orange County United Way,” said Steve Oswald, Chairman, President and Chief Executive Officer of Ducommun. “Regina and I have been very fortunate and believe it is important to give back to members of our community and the organizations that support them. Our Foundation began in 2015 and it was a dream and goal of mine from an early age to start one, so I am thrilled that we have been able to make a small difference with our philanthropy since that time. We also are particularly proud of Ducommun’s partnership with Orange County United Way and the generosity of our employees, whose commitment to their communities reflects the very best of our Company’s values.”

Sue Park, President and Chief Executive Officer of Orange County United Way, shared the following:
“We are incredibly grateful for Steve and Regina’s steadfast support, and it was an honor to present them with the Taking Action award at this year’s gala to shine a light on their impact. They are true leaders in every sense of the word, from personally committing their time as volunteers and initiating philanthropic funding when and where it is most needed, to inspiring Ducommun’s ongoing partnership and a major gift to The OC Way campaign. Because of their generosity, their leadership, and their unwavering commitment to turning influence into action, our community is stronger, more connected, and countless lives have been positively impacted.”

Ducommun’s partnership with Orange County United Way reflects the Company’s belief in the importance of corporate citizenship, community engagement, and investing in initiatives that strengthen families and improve lives.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added, innovative manufacturing solutions and products to customers in the aerospace, defense and industrial markets. Founded in 1849, the company specializes in two core areas – Electronic Systems and Structural Solutions – to produce complex products and components for commercial aircraft platforms, mission-critical military and space programs, and sophisticated industrial applications. For more information, visit Ducommun.com.

About Orange County United Way

Orange County United Way mobilizes communities to create brighter futures for all, today and for generations to come.

True to its founding spirit, whenever there is a need in the community, United Way is there. Through advocacy, collaboration, and innovative programming, its work is comprehensive and action-oriented, effectively addressing the county’s unique challenges.

From strengthening local resilience to expanding youth opportunity, financial stability, and access to stable housing, they’re working toward an Orange County where everyone has the support they need to reach their full potential.

To learn more, visit UnitedWayOC.org.

Orange County United Way is a stand-alone, independent 501(c)(3) non-profit organization.

CONTACTS:

Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665

COSTA MESA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) a global supplier of Engineered Products, Aftermarket and Value-Added Manufacturing Solutions for the aerospace and defense industry, is proud to announce that Chairman, President and Chief Executive Officer Stephen G. Oswald and his wife, Regina, were honored with the Taking Action Award at the Orange County United Way (OCUW) Annual Gala on November 7, 2026, in Laguna Niguel, California.

The Taking Action Award recognizes individuals whose generosity, leadership, and commitment to philanthropy create meaningful and lasting change in their communities. Steve and Regina were recognized for their longstanding dedication to giving back, their personal involvement in charitable initiatives, and their commitment to making a positive difference in the lives of others. Ducommun was also proud to serve as the Title Sponsor of this year’s gala, demonstrating the Company’s continued commitment to supporting the communities where its employees live and work.

“We are truly honored and humbled to receive this recognition from Orange County United Way,” said Steve Oswald, Chairman, President and Chief Executive Officer of Ducommun. “Regina and I have been very fortunate and believe it is important to give back to members of our community and the organizations that support them. Our Foundation began in 2015 and it was a dream and goal of mine from an early age to start one, so I am thrilled that we have been able to make a small difference with our philanthropy since that time. We also are particularly proud of Ducommun’s partnership with Orange County United Way and the generosity of our employees, whose commitment to their communities reflects the very best of our Company’s values.”

Sue Park, President and Chief Executive Officer of Orange County United Way, shared the following:
“We are incredibly grateful for Steve and Regina’s steadfast support, and it was an honor to present them with the Taking Action award at this year’s gala to shine a light on their impact. They are true leaders in every sense of the word, from personally committing their time as volunteers and initiating philanthropic funding when and where it is most needed, to inspiring Ducommun’s ongoing partnership and a major gift to The OC Way campaign. Because of their generosity, their leadership, and their unwavering commitment to turning influence into action, our community is stronger, more connected, and countless lives have been positively impacted.”

Ducommun’s partnership with Orange County United Way reflects the Company’s belief in the importance of corporate citizenship, community engagement, and investing in initiatives that strengthen families and improve lives.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added, innovative manufacturing solutions and products to customers in the aerospace, defense and industrial markets. Founded in 1849, the company specializes in two core areas – Electronic Systems and Structural Solutions – to produce complex products and components for commercial aircraft platforms, mission-critical military and space programs, and sophisticated industrial applications. For more information, visit Ducommun.com.

About Orange County United Way

Orange County United Way mobilizes communities to create brighter futures for all, today and for generations to come.

True to its founding spirit, whenever there is a need in the community, United Way is there. Through advocacy, collaboration, and innovative programming, its work is comprehensive and action-oriented, effectively addressing the county’s unique challenges.

From strengthening local resilience to expanding youth opportunity, financial stability, and access to stable housing, they’re working toward an Orange County where everyone has the support they need to reach their full potential.

To learn more, visit UnitedWayOC.org.

Orange County United Way is a stand-alone, independent 501(c)(3) non-profit organization.

CONTACTS:

Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
 The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
 Use a separate form for each offeror/offeree
Spire Healthcare Group plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e) Date position held/dealing undertaken:
 For an opening position disclosure, state the latest practicable date prior to the disclosure
11/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 1p ordinary
  Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled:        
(2) Cash-settled derivatives: 6,219,313 1.54    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:        
 TOTAL: 6,219,313 1.54    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b) Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
1p ordinary Equity swap Reducing a long position 30,673 2.4752 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 12/11/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.